## c.) Amendments to the Claims

## Claims 1-8 (Cancelled)

9. (New) A radicicol derivative represented by formula (I) or a pharmacologically acceptable salt thereof:

$$R_1O$$
  $O$   $CH_3$   $X$   $(I)$   $R^2O$   $R^4O$   $X$ 

wherein

R<sup>1</sup> and R<sup>2</sup> independently represent hydrogen, alkanoyl, alkenoyl, *tert*-butyldiphenylsilyl or *tert*-butyldimethylsilyl;

R<sup>3</sup> represents Y-R<sup>5</sup> wherein Y represents substituted or unsubstituted alkylene, or R<sup>3</sup> represents COR<sup>13</sup>, wherein neither R<sup>5</sup> nor R<sup>13</sup> are heterocyclic;

 $\label{eq:X-represents} X \text{ represents halogen, or is combined together with } R^4 \text{ to represent a}$  single bond; and

 $R^4$  is combined together with X to represent a single bond, or represents hydrogen, alkanoyl, alkenoyl, or -SO-Z, wherein Z is represented by formula (II):

 $R^{1A}O$  O  $CH_3$  O  $X^A$  (III)

wherein  $R^{1A}$  and  $R^{2A}$  have the same meaning as  $R^1$  and  $R^2$ , respectively;  $X^A$  represents halogen; and W represents O or N-O- $R^{3A}$  wherein  $R^{3A}$  has the same meaning as  $R^3$ , or a pharmacologically acceptable salt thereof.

- 10. (New) The compound according to Claim 9 wherein X is halogen, or a pharmacologically acceptable salt thereof.
- 11. (New) The compound according to Claim 9 wherein X is combined together with R<sup>4</sup> to represent a single bond, or a pharmacologically acceptable salt thereof.
- 12. (New) The compound according to Claim 11 wherein  $R^1$  and  $R^2$  each is hydrogen, or a pharmacologically acceptable salt thereof.
- 13. (New) The compound according to Claim 12 wherein R<sup>3</sup> is Y-R<sup>5</sup>, or a pharmacologically acceptable salt thereof.
- 14. (New) The compound according to claim 12 wherein R<sup>5</sup> is substituted or unsubstituted aryl, or a pharmacologically acceptable salt thereof.

- 15. (New) A composition, comprising at least one of the compounds according to any one of claims 9 to 14 or the pharmacologically acceptable salt thereof, together with a pharmacologically acceptable carrier.
- 16. (New) A method of treating disease mediated by tyrosine kinase, comprising administering to a patient in a need thereof an effective amount of the composition according to claim 15.